MetLife Investment Management’s Ionis Pharmaceuticals IONS Stock Holding History
Bought
Maintained
Sold
Other funds holding IONS
VPM
VCM
MetLife Investment Management's IONS Position: Q1 2026 in Review
MetLife Investment Management reduced its Ionis Pharmaceuticals (IONS) stake by 4.7% in Q1 2026, selling an estimated $35.5K and leaving 9,224 shares worth $693K. The position accounts for ﹤0.01% of the portfolio, ranked #1595.
MetLife Investment Management first reported a position in IONS in Q3 2018 and has held it in 20 quarters since. The position peaked at $765K in Q4 2025. 493 funds tracked by Wall St. Rank hold IONS as of Q1 2026.
- MetLife Investment Management held 9,224 shares of Ionis Pharmaceuticals worth $693K as of Q1 2026.
- MetLife Investment Management sold 450 Ionis Pharmaceuticals shares in Q1 2026, an estimated $35.5K.
- Ionis Pharmaceuticals made up ﹤0.01% of MetLife Investment Management's portfolio in Q1 2026, its #1595 holding.
- MetLife Investment Management first reported a position in Ionis Pharmaceuticals in Q3 2018 and has held it in 20 quarters since.
- MetLife Investment Management's Ionis Pharmaceuticals position peaked at $765K in Q4 2025.
- 493 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2026.
Based on MetLife Investment Management's 13F filing for Q1 2026, filed 14 May 2026.